Clinical Trial

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 19, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2020-03-11; most recent amendment 2025-06-16.
Status change: Recruiting → Active, Not Recruiting 2023-01-09
Status change: Not Yet Recruiting → Recruiting 2020-10-27
Trial Details
NCT Number NCT04305795
Lead Sponsor Rakuten Medical, Inc.
Conditions Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Enrollment 23 participants
Start Date 2020-12-21
Primary Completion 2026-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-19